1. Severe co-morbidity with life expectancy <3 months according to investigators assessment 2. ASAT/ALAT > 5 times the upper limit of normal 3. Acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. Known intolerance and hypersensitivity to any of the components of the available study drug. 5. Pregnancy or breast feeding 6. Any reason why, in the opinion of the investigators, the patient should not participate 7. Participation in a potentially confounding drug or device trial during the course of the study 8. Prolonged QTc interval (>470 ms) 9. Already receiving any of the study drugs 10. Patients with psoriasis 11. Patients on concomitant medication which is part of the list of prohibited medications have to be excluded from the current study (see protocol section 4.3)

1. Severe co-morbidity with life expectancy <3 months according to investigators assessment 2. ASAT/ALAT > 5 times the upper limit of normal 3. Acute co-morbidity within 7 days before inclusion such as myocardial infarction 4. Known intolerance and hypersensitivity to any of the components of the available study drug. 5. Pregnancy or breast feeding 6. Any reason why, in the opinion of the investigators, the patient should not participate 7. Participation in a potentially confounding drug or device trial during the course of the study 8. Prolonged QTc interval (>470 ms) 9. Already receiving any of the study drugs 10. Patients with psoriasis 11. Patients on concomitant medication which is part of the list of prohibited medications have to be excluded from the current study (see protocol section 4.3)